Flat feet
Also known as: Planus, Flat, Plano, Plani
Methodology & AI Transparency ⓘ
Flat feet Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Flat feet (also termed Planus or Flat)—coded clinically as M21.40 across Arthritis & Joints guidelines—combines topical/targeted anti-inflammatory therapy [Flat feet M21.40] with structured follow-up of Serum Uric Acid in Flat feet (M21.40: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M21.40)).
- 2 Real-world patient consensus: Diagnostic registry M21.40: Flat feet is managed within Arthritis & Joints (aka Planus).
- 3 Typical cash cost range: Workup highlights for Flat feet (M21.40): topical/targeted anti-inflammatory therapy [Flat feet M21.40].
- 4 Top reported side effects / signs: Longitudinal Flat feet monitoring tracks Weight-Bearing Joint Radiograph [Flat feet M21.40] toward Preserved joint-space width (M21.40).
Ask our AI Specialists anything about Flat feet
What Is Flat feet?
Flat feet (also termed Planus or Flat)—coded clinically as M21.40 across Arthritis & Joints guidelines—combines topical/targeted anti-inflammatory therapy [Flat feet M21.40] with structured follow-up of Serum Uric Acid in Flat feet (M21.40: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M21.40)).
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Flat feet (M21.40) center on monosodium urate or in Flat feet (M21.40: calcium pyrophosphate crystal). targeted arthritis & joints interventions aim to normalize Weight-Bearing Joint Radiograph [Flat feet M21.40].
Common Symptoms & Clinical Signs
- • Presentation of Flat feet (M21.40): brief morning joint in Flat feet (M21.40: stiffness)
- • Secondary Flat feet clinical sign: sudden, intensely painful, in Flat feet (M21.40: red swollen big-toe)
- • Symptom flares in Flat feet correlating with Weight-Bearing Joint Radiograph [Flat feet M21.40] deviation outside Preserved joint-space width (M21.40)
- • Functional arthritis & joints impact requiring topical/targeted anti-inflammatory therapy [Flat feet M21.40] evaluation (M21.40)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Flat feet Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M21.40 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Flat feet M21.40] | Preserved joint-space width (M21.40) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Flat feet (M21.40: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M21.40) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Flat feet (M21.40: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M21.40) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Flat feet
Treatment selection for Flat feet depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Flat feet)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Upadacitinib in autoimmune joint pain (rheumatoid arthritis) and Inadequate The 5-year benefit-risk profile for UPA in RA remains favorable. The Journal of rheumatology • 2024-07-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38621793 ↗ |
| Can This Approach Help? Inside the Latest Research on Upadacitinib in patients with psoriatic arthritis and inadequate response to Efficacy of upadacitinib was maintained up to 152 weeks of treatment in this highly treatment-refractory population of patients with PsA. Clinical and experimental rheumatology • 2023-11-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37404160 ↗ |
| Can This Approach Help? Inside the Latest Research on Type-I-error rate inflation in mixed models for repeated measures caused by However, the results of this simulation study rather underestimate the true T1E rate inflation. Pharmaceutical statistics • 2023-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37519010 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic In patients with nr-axSpA and objective signs of inflammation, long-term clinical outcomes achieved after 1 year were generally sustained at 3 years across MRI+/CRP+, MRI-/CRP+ and MRI+/CRP- subgroups. RMD open • 2024-05-09 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38724259 ↗ |
Flat feet Patient Community & “People Like Me” Threads
Filter Flat feet community threads and patient logs by age, biological sex, dosage, and treatment duration.